The U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL),an investigational basal insulin (Sanofi)
Diabetes News Service
The U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL),an investigational basal insulin (Sanofi)
For iPhone and iPad | For Android devices
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
Website by Wired up Wales